المؤلفون: Miao Zhao, Shan-Yan Lin, Jun Xue, Yong Gu, Ying Zhu, Hong-Na Wang, Chuan-Ming Hao, Xiaoye Zhu, Yuan-Cheng Chen

المصدر: Lupus: Open Access.

مصطلحات موضوعية: Nephrology, medicine.medical_specialty, Cyclophosphamide, business.industry, Lupus nephritis, Pharmacology, Omics, medicine.disease, Gastroenterology, Intravenous cyclophosphamide, Pharmacokinetics, Internal medicine, Pharmacogenomics, medicine, Clinical efficacy, business, medicine.drug

الوصف: Variations of clinical response of cyclophosphamide (CTX) treatment in lupus nephritis (LN) could still be recognized. LN patients with a GSTA1mutation (CT heterozygous) had a risk of none-response (P=0.005). Pharmacokinetics data indicated that patients with a GSTA1 heterozygous variant had a lower exposure to 4-OHCTX compared to wild-type patients (P=0.023). And clinical efficacy was significantly related to higher exposure to 4- OH-CTX (P=0.038). In conclusion, LN patients with GSTA1 heterozygousgenotypes had poor CTX treatment response due to less exposure to activated 4-OH-CTX.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1a5e19d763fbaaa74c056c7b36564705Test
https://doi.org/10.35248/2684-1630.16.1.115Test

المؤلفون: Pichaporn Artornsombudh, John H. Kempen

المصدر: Uveitis: An Update ISBN: 9788132222941

مصطلحات موضوعية: medicine.medical_specialty, genetic structures, business.industry, Legal blindness, Inflammation, medicine.disease, Dermatology, eye diseases, Intravenous cyclophosphamide, Chronic disease, medicine, medicine.symptom, business, Ocular inflammation, Uveitis

الوصف: Inadequately controlled uveitis is a leading cause of permanent visual loss, accounting for 5–20 % of cases of legal blindness [1–4]. Ocular inflammation is the principal cause of complications and morbidities. Delayed or inadequate control of inflammation can lead to serious sequelae resulting in visual impairment [5–8]. Therefore, the primary goal of management is to control the inflammation. There are two phases of treatment of ocular inflammation. First is induction of control of inflammation, the goal of which is to suppress the sight-threatening ocular inflammation as soon as possible with a rapidly effective medication, usually using topical, systemic, and/or injected corticosteroids. For remitting forms of uveitis, this may be the only treatment necessary. For chronic disease requiring suppressive therapy, the second aim is maintenance of control of inflammation after successful treatment in order to prevent recurrence or relapse of the ocular inflammation. Immunosuppressives have their primary role in maintenance of control of inflammation.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2a39117bc1bc05689ac892416048c715Test
https://doi.org/10.1007/978-81-322-2295-8_9Test

المؤلفون: Manabu Sugita, Keisuke Oda, Yutaka Nakiri, Yoshinari Takasaki, Satoshi Suzuki, Shihoko Nakajima, Taiki Ando, Kunimi Maeda

المصدر: Case Reports in Rheumatology, Vol 2016 (2016)
Case Reports in Rheumatology

مصطلحات موضوعية: 030203 arthritis & rheumatology, Cytopenia, Thrombotic microangiopathy, lcsh:Diseases of the musculoskeletal system, business.industry, Lupus nephritis, Case Report, General Medicine, Heparin, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Antecedent (behavioral psychology), Intravenous cyclophosphamide, hemic and lymphatic diseases, Immunology, Medicine, lcsh:RC925-935, business, skin and connective tissue diseases, medicine.drug

الوصف: A patient with severe lupus nephritis developed thrombocytopenia during treatment with high-dose steroids. In addition to viral- or disease-induced cytopenia, the pathology was believed to arise from diverse contributing factors, such as thrombotic microangiopathy and heparin-related thrombocytopenia (HIT). By combining plasma exchange therapy and intravenous cyclophosphamide, we successfully controlled the SLE activity and improved the thrombocytopenia. An antecedent bacterial infection or SLE activity is believed to have contributed to the concurrent HIT.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2738679a7ac594cbefddfcb6cddb4a75Test
https://doaj.org/article/0ec2e6d67cba45a6948188a8b51c9873Test

المؤلفون: Rajeev Jain, Vidya Limaye, Susanna Proudman, Tim Lu, Grant L. Raymond, Jern Yee Chen

المصدر: RETINAL Cases & Brief Reports. 6:111-115

مصطلحات موضوعية: medicine.medical_specialty, genetic structures, Intravenous methylprednisolone, medicine.diagnostic_test, Cyclophosphamide, business.industry, Retinal vasculitis, medicine.medical_treatment, Immunosuppression, General Medicine, Fundus (eye), medicine.disease, eye diseases, Surgery, Ophthalmology, Intravenous cyclophosphamide, immune system diseases, Angiography, medicine, skin and connective tissue diseases, business, Retinopathy, medicine.drug

الوصف: PURPOSE To report a case of systemic lupus erythematosus vaso-occlusive retinopathy with severe visual loss treated with intravenous pulsed cyclophosphamide. METHODS Retrospective interventional case report. RESULTS A 20-year-old Cambodian woman with newly diagnosed systemic lupus erythematosus presented with acute visual loss. Fluorescein fundus angiography demonstrated occlusive retinal vasculitis. Treatment with pulsed intravenous cyclophosphamide, intravenous methylprednisolone, and anticoagulation resulted in recovery of vision from count fingers to 6/6 in both eyes. CONCLUSION Early aggressive immunosuppression and anticoagulation for systemic lupus erythematosus retinal vasculitis can be beneficial in preventing disease progression and restoring vision. Further studies are needed to compare dosage regimens.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::325391d98cefcab61452aa2728a2ec0eTest
https://doi.org/10.1097/icb.0b013e3182160776Test

المؤلفون: Cees G. M. Kallenberg

المساهمون: Translational Immunology Groningen (TRIGR)

المصدر: Nephrology, Dialysis, Transplantation, 31(7), 1047-1052. Oxford University Press

مصطلحات موضوعية: PREDNISONE, medicine.medical_specialty, Cyclophosphamide, LONG-TERM, ERYTHEMATOSUS, 030232 urology & nephrology, Lupus nephritis, Azathioprine, Mycophenolate, MAINTENANCE TREATMENT, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, INTRAVENOUS CYCLOPHOSPHAMIDE, systemic lupus erythematosus, Clinical Protocols, Prednisone, Internal medicine, Euro-Lupus Nephritis Trial, medicine, Humans, IMMUNOSUPPRESSIVE THERAPY, MYCOPHENOLATE-MOFETIL, Antineoplastic Agents, Alkylating, TERM-FOLLOW-UP, 030203 arthritis & rheumatology, Transplantation, business.industry, Remission Induction, mycophenolate mofetil, medicine.disease, Lupus Nephritis, Regimen, Nephrology, Toxicity, Immunology, INDUCTION TREATMENT, Patient Compliance, TRIAL, business, Nephritis, medicine.drug

الوصف: Based on efficacy and toxicity considerations, both low-dose pulse cyclophosphamide as part of the Euro-Lupus Nephritis protocol and mycophenolate mofetil (MMF) with corticosteroids may be considered for induction of remission in patients with proliferative lupus nephritis. The long-term follow-up data available for low-dose pulse cyclophosphamide, the fact that compliance is guaranteed with this regimen and economic issues all favour the Euro-Lupus regimen in this author's opinion. For maintenance treatment, either azathioprine (AZA) or MMF may be used; AZA is preferred in case pregnancy is planned, while MMF is preferred when the disease relapses during use of AZA and, possibly, after successful induction of remission with MMF.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798d26230579d3c7eb75865f3f3e402aTest
https://pubmed.ncbi.nlm.nih.gov/27334842Test

المؤلفون: Mukunda Prasad Kafle, Mahesh Raj Sigdel, Dibya Singh Shah

المصدر: BMC Nephrology

مصطلحات موضوعية: Nephrology, Adult, Male, medicine.medical_specialty, Adolescent, Remission, 030232 urology & nephrology, Lupus nephritis, Renal function, Single Center, Gastroenterology, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, medicine, Humans, Hypoalbuminemia, Prospective Studies, Induction phase treatment, Cyclophosphamide, 030203 arthritis & rheumatology, business.industry, Cumulative dose, Remission Induction, Intravenous cyclophosphamide, Middle Aged, medicine.disease, Lupus Nephritis, Treatment Outcome, Immunology, Female, business, Complication, Nephritis, Immunosuppressive Agents, Follow-Up Studies, Research Article

الوصف: Background The current standard for induction phase treatment of lupus nephritis is steroid combined with mycophenolate mofetil or pulse intravenous cyclophosphamide (IVC). The lowest dose of IVC recommended for induction therapy is that used in the Euro-Lupus Trial. It is not known whether same cumulative dose of IVC would be effective when given over six months. Methods We carried out a prospective, observational study on 41 patients of biopsy-proven lupus nephritis (class III, IV, V or mixed). For induction, patients received six pulses of monthly IVC (500 mg each), along with steroid. Patients were followed up monthly until one month beyond completion of the sixth pulse. The outcomes assessed were complete remission (proteinuria 35 gm/L, stable estimated glomerular filtration rate (eGFR) if normal at baseline or increase in eGFR by 25 % if abnormal at baseline and normal urinary sediment), response (complete or partial remissions), complications of therapy and death. Results Twenty two patients (53.7 %) had class IV nephritis. Eighteen patients (43.9 %) achieved complete remission, 16 (39.0 %) achieved partial remission, yielding an overall response rate of 82.9 %. Nephrotic range proteinuria (UTP ≥ 3 g/day) and severe hypoalbuminemia (serum albumin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f852eb6465ce02e38c7b4f3f7a59d06cTest
https://pubmed.ncbi.nlm.nih.gov/27717323Test

المؤلفون: Lynettee Keyes-Elstein, Linda M. Griffith, Daniel E. Furst, Maureen D. Mayes, Richard A. Nash, Beverly Welch, Leslie J. Crofford, Keith M. Sullivan, Ellen Goldmuntz, Ashley Pinckney, Sharon Castina, Peter A. McSweeney

المصدر: Biology of Blood and Marrow Transplantation. 23:S23-S24

مصطلحات موضوعية: Transplantation, medicine.medical_specialty, business.industry, CD34, Hematology, medicine.disease, Scleroderma, Surgery, Clinical trial, 03 medical and health sciences, Haematopoiesis, 0302 clinical medicine, Intravenous cyclophosphamide, 030220 oncology & carcinogenesis, Autologous transplantation, Medicine, Organ involvement, Stem cell, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6221d46e0a149f866d4ae4f7967d5f80Test
https://doi.org/10.1016/j.bbmt.2017.01.012Test

المؤلفون: Shumpei Yokota, Syuji Takei, Masaaki Mori, Tomoyuki Imagawa, Takuji Murata

المصدر: Modern Rheumatology. 21:449-457

مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, business.industry, MEDLINE, Rheumatic disease, Off-Label Use, Off-label use, Pediatric drug, Regimen, Intravenous cyclophosphamide, Japan, Rheumatology, Antirheumatic Agents, Rheumatic Diseases, Injections, Intravenous, Drug approval, Humans, Medicine, Child, business, Cyclophosphamide, Drug Approval

الوصف: We created the final bill of "Intravenous cyclophosphamide (IVCY) for the treatment of rheumatic disease of children in general" in order to get approval for the off-label use of IVCY from the Study Group on Pediatric Drug Therapy. As a result, this study group approved IVCY's off-label use in children via public applications. We could create IVCY regimen specific for Japanese children independently of the efficacy, dosage, and administration applied in Germany, which at the time of application was the only country in Europe and the USA where IVCY was approved. Later, its use in adults was given approval through public applications after being fully reviewed by the Study Group on Unapproved and Off-label Drugs of High Medical Need. Consequently, IVCY is now available for the treatment of both childhood and adult rheumatic diseases in general.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a91a33b757c6d5d30352b6d2645e5adTest
https://doi.org/10.1007/s10165-011-0451-6Test

المؤلفون: Huiping Wang, Xiayu Li, Qun Li, Qiang He, Xuelin He, Fei Han, Suya Wang, Xiaohui Zhang, Guangyi Liu, Jianghua Chen

المصدر: American Journal of Nephrology. 33:185-192

مصطلحات موضوعية: Adult, Male, China, medicine.medical_specialty, Cyclophosphamide, Administration, Oral, Microscopic Polyangiitis, Mycophenolate, Gastroenterology, Remission induction, Intravenous cyclophosphamide, Adrenal Cortex Hormones, Induction therapy, Internal medicine, medicine, Humans, Prospective Studies, Infusions, Intravenous, Aged, Anti-neutrophil cytoplasmic antibody, business.industry, Body Weight, Remission Induction, Middle Aged, Mycophenolic Acid, medicine.disease, Treatment Outcome, Nephrology, cardiovascular system, Female, Microscopic polyangiitis, business, Vasculitis, Immunosuppressive Agents, Glomerular Filtration Rate, medicine.drug

الوصف: Aims: We prospectively compared the effects of oral mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) combined with corticosteroids for induction therapy of microscopic polyangiitis (MPA) with renal involvement over a follow-up period of 6 months. Methods: 41 MPA patients were randomly assigned to either the open-label MMF group or the IVC group. Patients in the MMF group (n = 19) received oral MMF 1.0 g/day (1.5 g/day for patients with a body weight >70 kg) and patients in the IVC group (n = 22) received IVC in monthly pulses of 1.0 g per pulse (0.8 g per pulse for patients with a body weight Results: There was no significant difference of estimated glomerular filtration rate (eGFR) level between the IVC and MMF groups at baseline. At 6 months, the eGFR level increased significantly in both groups, but there was no significant difference between the two. Three patients in the IVC group and 1 in the MMF group received maintenance dialysis within 6 months (p = 0.36). The remission rate was 63.6% in the IVC group and 78.9% in the MMF group (p = 0.23). Conclusion: MMF is effective for inducing remission in Chinese MPA patients and may represent an alternative therapy to monthly impulses of IVC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c903983b97293620b7e42f81b797e45Test
https://doi.org/10.1159/000324364Test

المؤلفون: Hideos Harigae, Ryu Watanabe, Tsuyoshi Shirai, Naruhiko Takasawa, Yumi Tajima, Hiroshi Fujii, Hiroshi Sato, Tomonori Ishii

المصدر: Internal Medicine. 50:53-57

مصطلحات موضوعية: Male, Hemolytic anemia, medicine.medical_specialty, Thrombotic microangiopathy, Prednisolone, Kidney, urologic and male genital diseases, Gastroenterology, Plasma, Intravenous cyclophosphamide, Recurrence, hemic and lymphatic diseases, Elevated lactate dehydrogenase, Internal medicine, Azathioprine, Ascites, Internal Medicine, Humans, Medicine, Blood Transfusion, Cyclophosphamide, Purpura, Thrombotic Thrombocytopenic, medicine.diagnostic_test, Thrombotic Microangiopathies, business.industry, General Medicine, Middle Aged, medicine.disease, Schistocyte, Surgery, Renal biopsy, medicine.symptom, business, Immunosuppressive Agents, medicine.drug

الوصف: A 46-year-old man presented with fever, thrombocytopenia, and a considerable accumulation of ascites. Although prednisolone and intravenous cyclophosphamide pulse (IVCY) were effective, he experienced recurrence. Renal insufficiency and hemolytic anemia developed subsequently. Schistocytes, negative Coombs' test, and elevated lactate dehydrogenase levels indicated thrombotic microangiopathy (TMA). He recovered well after receiving plasma infusion, IVCY, and prednisolone. Renal biopsy revealed subendothelial widening, thereby confirming TMA. This is a very rare case of TMA that presented with a considerable volume of ascites.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b823293065a3d315257006c3605d5d20Test
https://doi.org/10.2169/internalmedicine.50.4330Test